title,"Sponsors / Collaborators","Phase of Development","Clinical Trial Link","Mechanism of Action","Populations Tested In","FDA Designation","Nonprofit/Government Support","Presented at meetings",Location,"Mechanism Description","Phase of Development Devices","Type of Drug/Device",field_type_of_device_technique,US,"ct description",Software/Hardware/Both,"ex-US Approval","Year on Market" "Soticlestat (TAK-935)","Takeda Pharmaceuticals","Phase 3","https://clinicaltrials.gov/ct2/show/NCT05163314, https://clinicaltrials.gov/ct2/show/NCT04940624, https://skyline.researchstudytrial.com, https://skyway.researchstudytrial.com/",Other,"Developmental Epileptic Encephalopathies / Dravet syndrome and Lennox-Gastaut syndrome","Orphan Drug, Rare Pediatric Disease",N/A,"EILAT 2018 ASENT 2019 SNMMI 2019 AEDD 2019 EPC 2020 AAN 2020 AES 2020 AAN 2021 AES 2021 BPNA 2022 EILAT 202","United States, Australia, Belgium, Canada, China, France, Greece, Hungary, Italy, Japan, Latvia, the Netherlands, Poland, Serbia, Spain, Ukraine*, Russia* *No current active recruitment in these countries",": Cholesterol 24-hydroxylase (CH24H) Inhibitor Soticlestat exerts its potential effects via the inhibition of Cholesterol 24-hydroxylase (CH24H). CH24H converts cholesterol to 24S-hydroxycholesterol (24HC) in the brain. Reduction of 24HC has been shown to reduce glutamatergic signaling and inflammation, which may have downstream effects on seizure susceptibility.",,,,,,N/A,,